Compare Procter & Gamble Co (PG) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs TransMedics Group Inc — how do they compare? Procter & Gamble Co trades at $142.78 (market cap $338.13B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Procter & Gamble Co is far larger — about 110.5× TransMedics Group Inc's market cap, and Procter & Gamble Co pays a 2.99% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| PG | TMDX | |
|---|---|---|
Market Cap | $338.13B | $3.06B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Technology |
52-Week High | $167.18 | $150.42 |
52-Week Low | $138.10 | $61.99 |
Enterprise Value | $363.97B | $3.46B |
Dividend Yield | 2.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including a net income margin of 18.44% and ROE of 30.13%, though valuation ratios like P/E of 21.99 and P/S of 4.05 are at premiums to peers. Recent news highlights PG's dividend reliability and supply chain enhancements.
PG offers stability with consistent dividend growth and solid cash flows, but premium valuation and soft demand outlook pose near-term risks. Analyst consensus is bullish with a $161.20 price target, though technical weakness suggests potential consolidation. Key risks include economic sensitivity and competitive pressures, while institutional activity shows mixed positioning.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
